Biomind Labs Inc.

C$0.29As of Sun 8 Nov 2026, 12:00 UTC

CSE:BMNDHealthcare

Country Canada

PE (Fwd) —

TSR 5Y CAGR (29.43%)

Div yield —

ROE —

Biotechnology

Beta (5Y) 7.75

PE TTM —

TSR TTM (15.71%)

Mkt cap C$22.88M

ROIC —

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

$0.321

—

8.69%

—

TTM

FYE 31 Dec USD

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

◌—

Revenue$M

—

◌—

—

Revenue growth%

—

Gross margin%

—

Operating margin%

—

Net margin%

—

P/E ratio (avg)x

—

EV/EBITx

—

(1.44)

FCF yield (avg)%

—

(3.51)

(2.74)

(1.39)

(0.36)

—

(2.06)

—

FCF margin%

—

0.160

FCF / Net incomex

—

0.720

0.642

1.361

0.079

—

0.681

—

ROIC%

—

Return on equity%

—

(4153408.57)

Return on assets%

—

(3352.09)

(1607.10)

(632.83)

(2362255.56)

—

(2479.59)

—

(0.02)

EPS$

—

(0.04)

(0.02)

—

(0.01)

—

EPS growth%

—

60.06

78.55

(220.48)

—

60.06

—

(0.02)

Bookvalue per sh$

—

(0.02)

—

FCF per share$

—

(0.03)

(0.01)

—

Dividend per sh$

—

Div yield (avg)%

—

Payout ratio%

—

77.57

Shares (diluted)M

—

74.76

76.15

77.57

◌77.57

1.24%

—

Buyback yield%

—

(1.85)

(1.87)

◌—

(1.85)

—

(0.436)

D/E ratiox

—

(0.033)

(0.516)

(0.420)

(0.436)

(0.468)

—

17.03

Enterprise value$M

—

61.19

28.71

26.24

19.39

17.03

(31.83%)

—

LT debt$M

—

Peers (US$19.32M)

Cap (US$)

Defence Therapeutics…

19.04M

—

Resverlogix Corp.

18.28M

—

Quantum BioPharma Ltd.

17.83M

—

Pasithea Therapeutics…

19.34M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(19.47)

(12.36)

Own earn%

—

Sh yield%

—

(1.85)

Owners

Insiders/Inst%

36.31

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

—

EPS growth years

2/3

Dividend streakyrs

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions.

Revenue by segment

No breakdown available

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available